CTRI/2022/05/042484进行中（未招募）1 期
A Phase 1, Open Label First In Human Study Investigating the Safety, Tolerability, Pharmacokinetics,and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination WithAnti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects WithAdvanced Solid Tumors and Lymphomas.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects (=18 years of age) with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not accessible, not tolerated., Have progressed after =1 of systemic therapies for recurrent / metastatic disease and who have not received prior therapy targeting HPK1.
- •2. At least 1 measurable lesion as defined per RECIST 1.1/Cheson v.
- •3. Eastern Cooperative Oncology Group (ECOG) Performance Status = 1 measured within 72 hours of treatment.
- •4. Contraception: Double contraception is required for women with child bearing potential and men.
- •5. Willing and able to participate in the study and comply with all study requirements.
排除标准
- •1.Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study drug or interpretation of subject safety or study results.
- •2. Subjects with uncontrolled or untreated brain metastasis or leptomeningeal disease.
- •3. Active autoimmune diseases or history of autoimmune diseases that may relapse, with the following exceptions: a. Controlled Type 1 diabetes.
- •b. Hypothyroidism (provided that it is managed with hormone-replacement therapy only).
- •c. Controlled celiac disease.
- •d. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia).
- •4. Any active malignancy =2 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent.
- •5. Any condition that required systemic treatment with either corticosteroids ( >10 mg daily of prednisone or equivalent) or other immunosuppressive medication =14 days before the first dose of study drug(s), with the following exceptions: a. Adrenal replacement steroid (dose =10 mg daily of prednisone or equivalent).
- •b. Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption.
- •c. Short course (=7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a non-autoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen).
- •6. Any cancer directed therapy.
- •7. History of any of the following cardiovascular conditions in the past 12 months: a. Myocardial infarction
- •b. Unstable angina pectoris
- •c. Cardiac angioplasty or stenting
- •d. Coronary/peripheral artery bypass graft
- •e. Class III or IV congestive heart failure per New York Heart Association
- •f. Cerebrovascular accident or transient ischemic attack
- •8. History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases.
- •9. Pregnant/or planning to get pregnant or breast-feeding women.
- •10. Any evidence of serious active infections.
- •11. Subjects who test positive for hepatits B virus, hepatitis C virus or human immunodeficiency virus infection.
- •12. Any important medical illness or abnormal laboratory finding that would increase the risk of participating in this study (based on the Investigator’s judgment).
- •13. Any known severe allergic reaction to pembrolizumab/atezolizumab or its excipients. .
- •14. Subjects with history of phototoxicity
研究者
相似试验
尚未招募
1 期
A Phase 1, Open Label, First in Human (FIH) Study Investigating Photodynamic Therapy (PDT) with INV043 0.5% Ointment in Adults with Non-melanoma Skin Cancerson melanoma skin cancerNon melanoma skin cancerCancer - Non melanoma skin cancerACTRN12624000310561Invion Limited150
终止
1 期
A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumorseoplastic Disorder - Solid TumorsNeoplastic Disorder - Solid TumorsCancer - Any cancerACTRN12621001342808ChemoCentryx, Inc21
进行中（未招募）
1 期
A study to test the safety and effect of a new treatment for people with sight loss due to dry Age-related Macular DegeneratioEUCTR2017-003712-39-GBGyroscope Therapeutics
暂停
1 期
Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumorsadvanced solid tumorsJPRN-jRCT2031220077Ishibashi Hideyasu300
进行中（未招募）
1 期
The first study in humans testing a new drug called NVG-111 for blood and lymph gland cancerEUCTR2020-000820-20-GBovalGen Ltd90